Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T14:17:16.426Z.
Calculation as of: 2026-10-06T14:17:16.426Z.
Quote observation: 2026-10-06T14:13:29.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b407bf9ab9426f7f8731c51b1e955f2cfcbe23f9f3e819a9868889fb687bb4da
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Pasithea Therapeutics Corp.
Market Cap
$15.38M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.57M
Price/OCF Ratio
N/A
TTM Avg
57.00
3Y Avg
57.00
5Y Avg
57.00
Market Cap
$15.80M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.74M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.28M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.11M
Price/OCF Ratio
26.90
TTM Avg
28.16
3Y Avg
28.16
5Y Avg
28.16
Market Cap
$16.86M
Price/OCF Ratio
N/A
TTM Avg
43.53
3Y Avg
44.24
5Y Avg
48.21
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pasithea Therapeutics Corp. (KTTA) | $15.38M | N/A | N/A | N/A | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.57M | N/A | 57.00 | 57.00 | 57.00 |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.80M | N/A | N/A | N/A | N/A |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.74M | N/A | N/A | N/A | N/A |
| BioCardia, Inc. (BCDA)vs › | $16.22M | N/A | 64.40 | 51.01 | 44.81 |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.28M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $14.11M | 26.90 | 28.16 | 28.16 | 28.16 |
| Bionano Genomics, Inc. (BNGO)vs › | $16.75M | N/A | N/A | N/A | N/A |
| Dyadic International, Inc. (DYAI)vs › | $16.86M | N/A | 43.53 | 44.24 | 48.21 |
| IN8bio, Inc. (INAB)vs › | $13.43M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
